Showing results (81-90 of 128) with videos related to

Sort By:
Pageof 13
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 23, 2017
Clinical relevance and concordance of HER2 status in local and central testing-an analysis of 1581 HER2-positive breast carcinomas over 12 yearsBerit M Pfitzner, Bianca Lederer, Judith Lindner, et al.
International Journal of Cancer|December 20, 2021
mdm2 gene amplification is associated with luminal breast cancer progression in humanized PDX mice and a worse outcome of estrogen receptor positive diseaseAnja Kathrin Wege, Eva-Maria Rom-Jurek, Paul Jank, et al.
European Journal of Cancer (Oxford, England : 1990)|November 21, 2021
Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancerAndreas Schneeweiss, Laura L Michel, Volker Möbus, et al.
Breast Cancer Research : BCR|May 12, 2019
Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixtoElena Laakmann, Isabell Witzel, Peter A Fasching, et al.
Breast Cancer Research and Treatment|May 9, 2019
Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trialCarsten Denkert, Jan Budczies, Meredith M Regan, et al.
Breast Care (Basel, Switzerland)|June 1, 2023
Prevalence of Pathogenic Germline Variants in Women with Non-Familial Unilateral Triple-Negative Breast CancerKerstin Rhiem, Silke Zachariae, Anke Waha, et al.
NPJ Breast Cancer|May 14, 2025
Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantificationKristin Galas, Moritz Gleitsmann, Julia Rey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2024
An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical TrialsPaul Jank, Thomas Karn, Marion van Mackelenbergh, et al.
The New England Journal of Medicine|January 27, 2012
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancerGunter von Minckwitz, Holger Eidtmann, Mahdi Rezai, et al.
Breast Care (Basel, Switzerland)|June 15, 2022
Consensus Recommendations of the German Consortium for Hereditary Breast and Ovarian CancerKerstin Rhiem, Bernd Auber, Susanne Briest, et al.
Pageof 13